Risk Factors of Graft-Versus-Host Disease in the Iranian Allogeneic Hematopoietic Stem Cell Transplantation: A 10-Year Experience
Source : https://mjiri.iums.ac.ir/article-1-7006-en.html
Background: Graft-versus-host disease (GVHD) is a serious complication associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Thus, it is necessary to evaluate the risk factors of GVHD in allo-HSCT. Herein,...
Conclusion: In a nutshell, our results indicated that the donor-recipient gender disparity, the recipient's BMI, and CMV infection/reactivation status might be pivotal risk factors, which should be taken into account for prevention and management of GVHD.
Decreased Plasma Level of Cytokeratin 20 (KRT20) Is Indicative of the Emergence and Severity of Acute GvHD Irrespective to the Type of Organ Involvement - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35327321/
Accurate risk prediction of acute graft versus host disease (aGvHD) is currently an unmet clinical need. This study sought to analyze whether three plasma proteins expressed in a largely skin-...
Conclusion/Relevance: The discovery cohort (n = 39) revealed that at the time of diagnosis, plasma KRT20 showed a progressive decrease from unaffected individuals to patients with single-, and patients with multi-organ aGvHD. KRT20 was affected by cutaneous (p = 0.0263) and gastrointestinal aGvHD (p = 0.0242) independently and in an additive manner. Sensitivity and specificity of KRT20 for aGvHD involving both target organs (AUC = 0.852) were comparable to that of PI3 for skin-aGvHD (AUC = 0.708) or that of REG3A for gut-aGvHD (AUC = 0.855).
Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone?
Source : https://www.trasci.com/article/S1473-0502(22)00064-7/fulltext
Transfusion-associated graft-versus-host disease (TA-GvHD) is a rare but devastating disease with a very high mortality rate. Because of the high mortality and lack of effective treatments, the current state of...
Conclusion/Relevance: “Given that TA-GvHD is driven by contaminating white blood cells, and the fact that the international transfusion community has largely embraced leukoreduction, this raises the question as to whether the quantitative reduction of leukocytes via filtration can itself prevent TA-GvHD, thus allowing hospitals to skip irradiation steps? In this paper, we review the medical literature to determine how many leukocytes are needed to be removed to prevent TA-GvHD, while providing brief overviews of this entity itself and current irradiation strategies.”
External Validation of the HIGH-2-LOW Model: A Predictive Score for Venous Thromboembolism after Allogeneic Transplant - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35266218/
In patients undergoing hematopoietic cell transplantation (HCT), venous thromboembolism (VTE) remains a serious complication that lacks validated risk assessment models (RAM) to guide thromboprophylaxis. To address this dilemma, we performed...
Conclusions: The HIGH-2-LOW RAM identified allogeneic HCT recipients at high-risk for VTE in both validation cohorts. It can improve evidence-based decision-making for thromboprophylaxis post-transplant.
The immunosuppressant drug Cyclosporin A aggravates irradiation effects in endothelial cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35272142/
The immunosuppressant drug Cyclosporin A (CsA) has been widely used to prevent the development of Graft-versus-Host Disease (GvHD) that can occur after transplantation, including allogeneic graft after accidental high-dose irradiation...
Conclusions: Altogether, these results suggest that post-transplant CsA treatment may exacerbate the deleterious effects of irradiation on the endothelium.
Low incidence of hyperacute graft-versus-host disease (GVHD) with effective GVHD prophylaxis based on anti-thymocyte globulin - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35245388/
doi: 10.1111/bjh.18099. Online ahead of print. 1 APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France. 2 Clinical Hematology and Bone Marrow Transplant Centre, S. Maria...
Conclusion: Overall, development of new strategies such as RTC and generalisation of in vivo T-cell depletion with ATG and/or PTCy, translate into a decreased incidence of haGVHD. Furthermore, despite a higher incidence of cGVHD in patients with haGVHD compared to aGVHD after day 14, NRM and OS were similar. This suggests that patients with haGVHD should no longer be excluded from clinical trials investigating new agents for aGVHD.9